Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Acorda Therapeutics

Biotech & Life Sciences · Town of Orangetown, United States · Founded 1995 · IPO 2006 Thoroughbred

A publicly traded biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders

Valuation
$161M
Market cap · 2026
Revenue
$139M
Latest reported FY
EBITDA
$9.0M
Latest reported FY

Investors

10 investors on Acorda Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Swiss Life
BayStar Capital
Forward Ventures
Series B+ 7 investors entered at this stage
TVM Capital Life Science
Merrill Lynch
Cross Atlantic Partners
MPM BioImpact
JP Morgan
Easton Capital Investment Group
ABN AMRO

Global footprint

Where Acorda Therapeutics has talent and traffic

Workforce by country
2 countries with
team presence
🇺🇸 United States96.6%
🇮🇳 India2.2%
2 countries shown
Web traffic by country
680 monthly visits
across markets
🇺🇸 United States102.9%
Top 1 markets shown

Capital deployed

Acorda Therapeutics's 3 investments and acquisitions.

Every disclosed deal where Acorda Therapeutics appeared as a backer or acquirer, 2012–2016. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

3 deals across Acorda Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Acorda Therapeutics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        3 of 3 deals

        Market sentiment

        What the market is saying about Acorda Therapeutics

        An AI-synthesized read of the highest-engagement posts about Acorda Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Acorda Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.